Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
loncastuximab tesirine + roflumilast + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Unknown
- Lead developer
- ADC Therapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Lo-RR-CHOP is an investigational combination therapy regimen being evaluated by The University of Texas Health Science Center at San Antonio for the treatment of treatment-naïve, high-risk diffuse large B-cell lymphoma (DLBCL). The regimen adds loncastuximab tesirine, a CD19-directed antibody-drug conjugate (ADC) carrying a pyrrolobenzodiazepine (PBD) dimer payload, and roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, to the standard-of-care R-CHOP chemotherapy backbone (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). This multi-modal approach aims to improve outcomes in patients with high-risk DLBCL (NCCN-IPI risk score ≥2) by simultaneously targeting CD19-expressing B-lymphocytes, modulating intracellular signaling pathways via PDE4 inhibition, and utilizing the established cytotoxic and immunological effects of standard chemo-immunotherapy.
- Other names
- Loncastuximab and Roflumilast added to R-CHOP
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNA minor groovePDE4 (Phosphodiesterase 4A1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on loncastuximab tesirine + roflumilast + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on loncastuximab tesirine + roflumilast + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.